Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, Amsterdam, The Netherlands.
Department of Oral and Maxillofacial Surgery/Oral Pathology, Amsterdam UMC and Academic Centre for Dentistry Amsterdam (ACTA), Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, Amsterdam, The Netherlands.
Stem Cells Transl Med. 2023 Sep 15;12(9):617-630. doi: 10.1093/stcltm/szad045.
This prospective cohort study aimed to assess long-term safety, dental implant survival, and clinical and radiological outcomes after maxillary sinus floor elevation (MSFE; lateral window technique) using freshly isolated autologous stromal vascular fraction (SVF) combined with calcium phosphate ceramics. All 10 patients previously participating in a phase I trial were included in a 10-year follow-up. They received either β-tricalcium phosphate (β-TCP; n = 5) or biphasic calcium phosphate (BCP; n = 5) with SVF-supplementation on one side (study). Bilaterally treated patients (6 of 10; 3 β-TCP, 3 BCP) received only calcium phosphate on the opposite side (control). Clinical and radiological assessments were performed on 44 dental implants at 1-month pre-MSFE, and 0.5- to 10-year post-MSFE. Implants were placed 6 months post-MSFE. No adverse events or pathology was reported during a 10-year follow-up. Forty-three dental implants (98%) remained functional. Control and study sides showed similar peri-implant soft-tissue quality, sulcus bleeding index, probing depth, plaque index, keratinized mucosa width, as well as marginal bone loss (0-6 mm), graft height loss (0-6 mm), and graft volume reduction. Peri-implantitis was observed around 6 implants (control: 4; study: 2) in 3 patients. This study is the first to demonstrate the 10-year safety of SVF-supplementation in MSFE for jawbone reconstruction. SVF-supplementation showed enhanced bone regeneration in the short term (previous study) and led to no abnormalities clinically and radiologically in the long term.
本前瞻性队列研究旨在评估使用新鲜分离的自体基质血管成分 (SVF) 联合磷酸钙陶瓷进行上颌窦底提升 (MSFE; 侧窗技术) 的长期安全性、牙种植体存活率以及临床和影像学结果。所有 10 名先前参与 I 期试验的患者均纳入 10 年随访。他们在一侧接受β-磷酸三钙 (β-TCP; n = 5) 或双相磷酸钙 (BCP; n = 5) 与 SVF 联合治疗(研究组)。10 名患者中的 6 名双侧治疗患者(3 名β-TCP，3 名 BCP)在对侧仅接受磷酸钙治疗(对照组)。在 MSFE 前 1 个月、MSFE 后 0.5-10 年对 44 颗牙种植体进行临床和影像学评估。MSFE 后 6 个月植入种植体。在 10 年随访期间未报告任何不良事件或病理学。43 颗牙种植体 (98%) 仍保持功能。对照组和研究组的种植体周围软组织质量、龈沟出血指数、探诊深度、菌斑指数、角化黏膜宽度以及边缘骨吸收 (0-6mm)、移植物高度损失 (0-6mm) 和移植物体积减少均相似。3 名患者的 6 颗种植体 (对照组:4 颗;研究组:2 颗)周围观察到种植体周围炎。本研究首次证明了 SVF 在上颌窦底提升骨重建中应用的 10 年安全性。SVF 补充在短期内显示出增强的骨再生作用(先前的研究)，并且在长期内临床和影像学上没有异常。
